Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. Jundishapur Journal of Microbiology
  4. Articles

  5. Incidence of Helicobacter pylori in central serous chorioretinopathy: a case control study
  6. Scopus by Title (Ref)

Jundishapur Journal of Microbiology

Ahvaz Jundishapur University of Medical Sciences

Home
Current IssueAll IssuesIn PressAccepted ManuscriptsSearch
Instructions
Journal InformationEditors & BoardsIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormSupportContact Us
APC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. Association between central serous chorioretinopathy and Helicobacter pylori infection: a systematic review and Meta-analysis

- Wu D.W. , et al.

2. The relation between Helicobactor pylori gastrointestinal tract infection and central serous chorioretinopathy among patients in Al-Diwaniya province

- Layikh H. , et al.

3. Oral medications for central serous chorioretinopathy: a literature review

- Fusi-Rubiano W. , et al.

4. Association of Helicobacter pylori with central serous chorioretinopathy in Iranian patients

- Roshani M. , et al.

5. Treatment for helicobacter pylori infection, an overview

- Hajiani E. , et al.

HomeInstructionsAPC

Articles

  • Current Issue
  • All Issues
  • In Press
  • Accepted Manuscripts
  • Search

About Journal

  • Journal Information
  • Editors & Boards
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.